Why is Gaudium IVF and Women Health Ltd falling/rising?

As of 25-Aug, Gaudium IVF and Women Health Ltd's stock price is rising, currently at 116.00, reflecting an increase of 2.25 (1.98%). This upward movement can be attributed to several factors. The stock has outperformed its sector by 0.44% today and has shown consecutive gains over the last two days, accumulating a total return of 3.99% during this period. Additionally, there has been a significant increase in investor participation, with delivery volume rising by 172.72% compared to the 5-day average, indicating heightened interest in the stock. Furthermore, while the stock is currently below the 5-day, 20-day, and 50-day moving averages, it remains above the 100-day and 200-day moving averages, suggesting a potential positive trend in the longer term. Overall, these factors contribute to the stock's rising price.

Which are the latest news on Gaudium IVF?

Gaudium IVF Falls 9.53%: 3 Key Factors Driving the Weekly Decline Gaudium IVF and Women Health Ltd: Valuation Shift Signals Price Attractiveness Change

Should I buy, sell or hold Gaudium IVF and Women Health Ltd?

Based on the current performance and indicators for Gaudium IVF and Women Health Ltd, it would be advisable to consider a strong sell position. The company has reported negative results recently, with net sales falling by 25.7% compared to the previous four-quarter average and a significant drop in profit after tax (PAT) by 70.9%. Additionally, the valuation appears expensive with a high enterprise value to capital employed ratio of 5.4, despite a return on capital employed (ROCE) of 20.9%. The decline in institutional investor participation, with a 4.08% decrease in their stake, suggests a lack of confidence from more experienced investors.While the company is net-debt free, which is a positive aspect, the overall trend in sales and profitability raises concerns about its short-term performance. Given these factors, it may be prudent to sell or avoid investing further in the company at this time.

What does Gaudium IVF do?

Overview:Gaudium IVF and Women Health Ltd operates in the healthcare services industry and is classified as a micro-cap company.History:The incorporation year and any status changes are not provided. The latest quarterly results reported are for June 2026, showing net sales and profit.Financial Snapshot:Most recent Net Sales: 19 Cr (Quarterly Results - Jun 2026) Most recent Net Profit: 2 Cr (Quarterly Results - Jun 2026) Market-cap value: INR 898 Cr (Micro Cap)Key Metrics:P/E: 33.00 Industry P/E: 67 Dividend Yield: 0.00% Debt-Equity: 0.10 Return on Equity: 16.08% Price-to-Book: 5.90 Contact Details:Registrar Address: Not available. Phone: Not available. Email: Not available. Website: Not available.

Who are the peers of the Gaudium IVF?

Peers: The peers of Gaudium IVF are One Global Serv, Laxmi Dental, 3B Blackbio, Health X Platfor, Hemant Surgical, Prevest Denpro, Take Solutions, Nureca.Quality Snapshot: Excellent management risk is observed at Prevest Denpro, while Average management risk is found at One Global Serv, Laxmi Dental, 3B Blackbio, Hemant Surgical, and the rest. Below Average management risk is noted at Health X Platfor, Take Solutions, and Nureca. Growth is Excellent at One Global Serv, Good at Laxmi Dental and Hemant Surgical, while Below Average growth is seen at 3B Blackbio, Health X Platfor, and the rest. Gaudium IVF's peers with Good capital structure include Hemant Surgical, while Excellent capital structure is noted at One Global Serv, Laxmi Dental, 3B Blackbio, Health X Platfor, Prevest Denpro, and the rest. Below Average capital structure is found at Take Solutions, while Nureca has a Good capital structure.Return Snapshot: The peer with the highest 1-year return is One Global Serv at 121.51%, while Laxmi Dental has the lowest at -45.84%. Gaudium IVF's 1-year return data is not available for comparison. Additionally, peers with negative six-month returns include Take Solutions and 3B Blackbio.

GAUDIUMIVF Share Price | Gaudium IVF and Women Health Ltd Stock Analysis & Recommendation

Key Events This Week

17 Aug: Downgrade to Strong Sell amid weak financial and technical trends

17 Aug: Technical momentum shifts to mildly bearish

21 Aug: Valuation grade shifts from very expensive to expensive

21 Aug: Week closes at Rs.111.55 (-9.53%)

Week Open

Rs.123.30

Week Close

Rs.111.55Read full news article

Gaudium IVF and Women Health Ltd: Valuation Shift Signals Price Attractiveness Change

Gaudium IVF and Women Health Ltd, a micro-cap player in the Healthcare Services sector, has seen a notable shift in its valuation parameters, moving from a 'very expensive' to an 'expensive' rating. This change reflects a recalibration in price attractiveness amid evolving market dynamics and peer comparisons, with the company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios signalling a less compelling investment case despite solid operational metrics.

Read full news article

Gaudium IVF Downgraded to Strong Sell Amidst Weak Financial and Technical Trends

Gaudium IVF and Women Health Ltd has been downgraded from a Sell to a Strong Sell rating by MarketsMOJO as of 15 August 2026, reflecting deteriorating financial performance, weakening technical indicators, and an expensive valuation despite some revenue growth. The micro-cap healthcare services company faces significant challenges that have prompted a reassessment of its investment appeal.

Read full news article

[ { "link": "quarterly", "btn_text": "All Quarterly Results", "header": "Quarterly Results Snapshot (Standalone) - Jun'26 - QoQ", "rhs": [ { "prefix": "Net Sales ", "suffix": "QoQ Growth in quarter ended Jun 2026 is -38.29% vs 56.24% in Mar 2026", "dir": -1 }, { "prefix": "Standalone Net Profit ", "suffix": "QoQ Growth in quarter ended Jun 2026 is -78.53% vs 143.08% in Mar 2026", "dir": -1 } ], "table": { "header": [ "Jun'26", "Mar'26", "Change(%)" ], "body": [ { "field": "Net Sales", "val1": "13.68", "val2": "22.17", "chgp": "-38.29%", "chgp_class": "negative" }, { "field": "Operating Profit (PBDIT) excl Other Income", "val1": "2.18", "val2": "11.27", "chgp": "-80.66%", "chgp_class": "negative" }, { "field": "Interest", "val1": "0.32", "val2": "1.24", "chgp": "-74.19%", "chgp_class": "positive" }, { "field": "Exceptional Items", "val1": "0.00", "val2": "0.00", "chgp": "", "chgp_class": "neutral" }, { "field": "Standalone Net Profit", "val1": "1.66", "val2": "7.73", "chgp": "-78.53%", "chgp_class": "negative" }, { "field": "Operating Profit Margin (Excl OI)", "val1": "15.94%", "val2": "50.83%", "chgp": "-34.89%", "chgp_class": "negative" } ] } }, { "link": "half-yearly", "btn_text": "All Half Yearly Results", "alert": "No Half Yearly Results declared by Gaudium IVF" }, { "link": "nine-monthly", "btn_text": "All Nine Monthly Results", "alert": "No Nine Monthly Results declared by Gaudium IVF" }, { "link": "annual", "btn_text": "All Annual Results", "header": "Annual Results Snapshot (Standalone) - Mar'26", "rhs": [ { "prefix": "Net Sales ", "suffix": "YoY Growth in year ended Mar 2026 is 21.32% vs 12.98% in Mar 2025", "dir": 1 }, { "prefix": "Standalone Net Profit ", "suffix": "YoY Growth in year ended Mar 2026 is 19.65% vs 11.96% in Mar 2025", "dir": 1 } ], "table": { "header": [ "Mar'26", "Mar'25", "Change(%)" ], "body": [ { "field": "Net Sales", "val1": "71.58", "val2": "59.00", "chgp": "21.32%", "chgp_class": "positive" }, { "field": "Operating Profit (PBDIT) excl Other Income", "val1": "34.57", "val2": "27.86", "chgp": "24.08%", "chgp_class": "positive" }, { "field": "Interest", "val1": "3.36", "val2": "1.39", "chgp": "141.73%", "chgp_class": "negative" }, { "field": "Exceptional Items", "val1": "0.00", "val2": "0.00", "chgp": "", "chgp_class": "neutral" }, { "field": "Standalone Net Profit", "val1": "22.29", "val2": "18.63", "chgp": "19.65%", "chgp_class": "positive" }, { "field": "Operating Profit Margin (Excl OI)", "val1": "48.30%", "val2": "47.22%", "chgp": "1.08%", "chgp_class": "positive" } ] } } ]